AU9805398A - Novel human egf receptors and use thereof - Google Patents

Novel human egf receptors and use thereof

Info

Publication number
AU9805398A
AU9805398A AU98053/98A AU9805398A AU9805398A AU 9805398 A AU9805398 A AU 9805398A AU 98053/98 A AU98053/98 A AU 98053/98A AU 9805398 A AU9805398 A AU 9805398A AU 9805398 A AU9805398 A AU 9805398A
Authority
AU
Australia
Prior art keywords
novel human
human egf
egf receptors
receptors
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU98053/98A
Inventor
Gabriel Corfas
Klaus Elenius
Michael Klagsbrun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of AU9805398A publication Critical patent/AU9805398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU98053/98A 1997-10-15 1998-10-15 Novel human egf receptors and use thereof Abandoned AU9805398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6237397P 1997-10-15 1997-10-15
US60062373 1997-10-15
PCT/US1998/021828 WO1999019488A1 (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Publications (1)

Publication Number Publication Date
AU9805398A true AU9805398A (en) 1999-05-03

Family

ID=22042059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU98053/98A Abandoned AU9805398A (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Country Status (2)

Country Link
AU (1) AU9805398A (en)
WO (1) WO1999019488A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2662581T3 (en) 1999-06-25 2018-04-09 Immunogen, Inc. Treatment methods using anti-ErbB-maitansinoid antibody conjugates
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
NZ517150A (en) 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
JP2003534292A (en) 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド ERBB antagonist gene detection assays to increase the likelihood of effective response to cancer treatment
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
US6255111B1 (en) 2000-07-31 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of Her-4 expression
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
DK2263691T3 (en) 2002-07-15 2012-10-22 Hoffmann La Roche Treatment of cancer with the recombinant humanized monoclonal anti-ErbB2 antibody 2C4 (rhuMAb-2C4)
CN102973947A (en) 2004-06-01 2013-03-20 健泰科生物技术公司 Antibody-drug conjugates and methods
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
MX2007009889A (en) 2005-02-23 2007-09-07 Genentech Inc Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor.
EP2132573B1 (en) 2007-03-02 2014-04-23 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
RU2011119638A (en) * 2008-10-17 2012-11-27 Дженентек, Инк. METHOD OF TREATMENT
KR101789338B1 (en) * 2008-11-25 2017-10-23 제넨테크, 인크. Isoform specific anti-her4 antibodies
KR20150036824A (en) 2009-03-20 2015-04-07 제넨테크, 인크. Bispecific anti-her antibodies
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche Multispecific antibodies, antibody analogs, compositions, and methods
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN103080134B (en) 2010-08-20 2015-11-25 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
JP6297490B2 (en) 2011-08-31 2018-03-20 ジェネンテック， インコーポレイテッド Diagnostic marker
MX2014006529A (en) 2011-11-30 2014-11-25 Genentech Inc Erbb3 mutations in cancer.
BR112014013412A8 (en) 2011-12-05 2021-06-08 Novartis Ag antibodies to epidermal growth factor receptor 3 (her3), and their uses
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
CN107002119A (en) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 Treatment of cancer and the former and associating that HGF is expressed using C MET antagonists
ES2729202T3 (en) 2014-07-16 2019-10-30 Dana Farber Cancer Inst Inc Et Al Inhibition of HER3 in low grade serous ovarian cancers
AU2018258263A1 (en) 2017-04-24 2019-10-24 Genentech, Inc. ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012019A2 (en) * 1994-10-14 1996-04-25 Bristol-Myers Squibb Company Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family

Also Published As

Publication number Publication date
WO1999019488A1 (en) 1999-04-22
WO1999019488A8 (en) 1999-10-14
WO1999019488A9 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
AU9805398A (en) Novel human egf receptors and use thereof
AU5752398A (en) Novel ketobenzamides and their use
AU694696B2 (en) Sulfonamides and their use
AU3728197A (en) Human telomerase
AU7718898A (en) Txu-7-pap immunotoxin and use thereof
AU6030398A (en) Human proteins
AU8905098A (en) Skin care compositions and use
AU9781998A (en) Huchordin and uses thereof
AU4266596A (en) Composition and use
AU1926000A (en) Pth1r and pth3r receptors
AU1968400A (en) Human vanilloid receptors and their uses
GB9717598D0 (en) Novel composition and use
AU1592099A (en) Skin care composition
AU4522796A (en) Human somatostatin-like receptor
AU8815298A (en) Improvements relating to surgical devices and their location
AU3634595A (en) Bis-oxazolidines and their use
AU9017598A (en) Human frezzled-like protein
AU5918598A (en) Human extracellular matrix-1
AU6035398A (en) Human c5a-like receptor
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU3116697A (en) Human interleukin-1j and antagonists thereof
AU5763098A (en) Arylthio-dithiazindioxides and their use as pesticides
AU8019494A (en) Human endothelin-bombesin receptor
HUP9800247A3 (en) Promoter for human endoglingene and its use
AU1645599A (en) Human matrilin-3

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase